Image via Pharma Times
UCB: Partnership
UCB expanded its existing alliance with Cancer Research UK, adding two new UCB-nominated projects to advance novel cancer therapies
Source: Pharma Times
The leadership read
Alliances like this can broaden biotech & pharma commercial leadership bench strength.
Market context: This lands while the Talent Market Index reads 98.6 (Neutral) — down 1.4 versus the prior month — and EMEA signal share is steady (-1.1pts).
UCB: 2 signals in the last 90 days — above the Biotech & Pharma median of 1 across 19 tracked companies; 0.1% of MitchelLake's EMEA signal flow; 2 tracked across 17 days.
MitchelLake in this thematic
Also at UCB →
More signals across Biotech & Pharma
Partnership · EMEA
Thermo Fisher Scientific →Thermo Fisher Scientific awarded UK government contract: "Supply of 2 Ion Chromatography systems" — buyer: Nuclear Restoration Services Limited
Product Launch · EMEA
Bristol Myers Squibb →Bristol Myers Squibb reported positive Phase III clinical trial results for mezigdomide (multiple myeloma) and early-stage CAR T-cell therapy arlocabtagene autoleucel with strong response rates and manageable safety profiles, presented at European Hematology Association Congress 2026.
Restructuring · EMEA
Boehringer Ingelheim →Boehringer Ingelheim reducing investments in Germany by $1 billion due to lack of investment predictability in pharmaceutical sector
Product Launch · EMEA
Amgen →European Commission approved Amgen's IMDYLLTRA® for extensive-stage small cell lung cancer treatment, demonstrating 40% reduction in death risk versus chemotherapy in Phase 3 trial
Ma Activity · EMEA
Biogen →Biogen completed acquisition of Apellis Pharmaceuticals, a leader in complement-driven disease treatments
Leadership Change · EMEA
BioMarin Pharmaceutical Inc. →Ian T. Clark elected as new Chair of the Board, replacing retiring Richard A. Meier
Intelligence powered by Autonodal ↗